On August 1, 2022, Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization.

Wilson Sonsini Goodrich & Rosati advised Marengo on patent matters related to the transaction. The team includes Lou Lieto, Chris McAndrew, Angel Wang, and Moonkyoung Um.

For more information, please see the press release.